<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552888</url>
  </required_header>
  <id_info>
    <org_study_id>TulaneU</org_study_id>
    <secondary_id>1U54GM104940</secondary_id>
    <nct_id>NCT02552888</nct_id>
  </id_info>
  <brief_title>Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial</brief_title>
  <acronym>NICE</acronym>
  <official_title>Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tulane University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed randomized controlled trial will test the safety and efficacy of combination&#xD;
      therapy with sodium nitrite and isoquercetin on endothelial function and inflammation among&#xD;
      patients with chronic kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed randomized controlled trial will test the safety and efficacy of combination&#xD;
      therapy with sodium nitrite and isoquercetin on endothelial function and inflammation among&#xD;
      patients with chronic kidney disease. Investigators will recruit 70 albuminuric CKD patients&#xD;
      and randomly assign participants to combination therapy with sodium nitrite and isoquercetin&#xD;
      or placebo for three months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percentage Change in Endothelium-dependent Flow-mediated Vasodilation (FMD) Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>FMD was measured using high resolution ultrasound on the brachial artery. FMD was calculated as the maximal percentage change in vessel size during hyperemia . The mean changes between baseline, 6 weeks and 12 weeks in FMD with 95% CI were calculated using linear mixed effects model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Endothelial Function Biomarkers VCAM-1, ICAM-1, E-selectin and vWF Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of Vascular Adhesion Molecule-1(VCAM-1), Intercellular Adhesion Molecule-1 (ICAM-1), E-selectin, and von Willebrand Factor (vWF). The mean changes between baseline, 6 weeks and 12 weeks in VCAM-1, ICAM-1, E-selectin and vWF with 95% CI were calculated using linear mixed effects model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Endothelial Function Biomarker Asymmetrical DiMethylArginine (ADMA) Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of Asymmetrical DiMethylArginine (ADMA). The mean changes between baseline, 6 weeks and 12 weeks in ADMA with 95% CI were calculated using linear mixed effects model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Endothelial Function Biomarker Endostatin Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of endostatin. The mean changes between baseline, 6 weeks and 12 weeks in endostatin with 95% CI were calculated using linear mixed effects model, and the log transformed endostatin was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Endothelial Function Biomarker Urine Epidermal Growth Factor (UEGF) Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>A urine sample was taken for each participant to measure the levels of Urine Epidermal Growth Factor (UEGF). The mean changes between baseline, 6 weeks and 12 weeks in UEGF with 95% CI were calculated using linear mixed effects model, and the log transformed Urine EGF/creatinine ratio was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Inflammatory Biomarker C-Reactive Protein (CRP) Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of C-Reactive Protein (CRP). The mean changes between baseline, 6 weeks and 12 weeks in CRP with 95% CI were calculated using linear mixed effects model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Inflammatory Biomarkers Tumor Necrosis Factor-α (TNF-a), Interleukin-17 (IL-17), Interleukin-1β (IL-1beta), and Monocyte Chemoattractant Protein-1 (MCP-1) Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of Tumor Necrosis Factor-α (TNF-a), interleukin-17 (IL-17), interleukin-1β (IL-1beta), and Monocyte Chemoattractant Protein-1 (MCP-1). The mean changes between baseline, 6 weeks and 12 weeks in TNF-a, IL-17, IL-1beta, MCP-1 with 95% CI were calculated using linear mixed effects model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Inflammatory Biomarker Interleukin-6 (IL-6) Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of interleukin-6 (IL-6). The mean changes between baseline, 6 weeks and 12 weeks in interleukin-6 (IL-6) with 95% CI were calculated using linear mixed effects model, and the log transformed IL-6 was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Oxidative Stress Biomarker Low-density Lipoprotein (LDL) Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of low-density lipoprotein (LDL). The mean changes between baseline, 6 weeks and 12 weeks in LDL with 95% CI were calculated using linear mixed effects model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Oxidative Stress Biomarker Nitrotyrosine Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of nitrotyrosine. The mean changes between baseline, 6 weeks and 12 weeks in nitrotyrosine with 95% CI were calculated using linear mixed effects model.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean Percentage Change in Methemoglobin Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of methemoglobin. The mean percentage change between baseline, 6 weeks and 12 weeks in methemoglobin with 95% CI was calculated using linear mixed effects model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Isoquercetin Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of isoquercetin. The mean changes between baseline, 6 weeks and 12 weeks in isoquercetin with 95% CI were calculated using linear mixed effects model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Plasma Nitrite Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of plasma nitrite. The mean changes between baseline, 6 weeks and 12 weeks in plasma nitrite with 95% CI were calculated using linear mixed effects model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Estimated-Glomerular Filtration Rate (eGFR) Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>Estimated-Glomerular Filtration Rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. The equation is GFR = 141 * min(Scr/κ,1)α * max(Scr/κ, 1)-1.209 * 0.993Age * 1.018 [if female] * 1.159 [if black]. Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. The mean changes between baseline, 6 weeks and 12 weeks in eGFR with 95% CI were calculated using linear mixed effects model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Lipid Profile Biomarkers Total Cholesterol, Low Density Lipoprotein (LDL)-Cholesterol and High Density Lipoprotein (HDL)-Cholesterol Over 12 Weeks</measure>
    <time_frame>Baseline,12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of total cholesterol, Low Density Lipoprotein (LDL)-cholesterol and High Density Lipoprotein (HDL)-cholesterol. The mean changes between baseline and 12 weeks in total cholesterol, Low Density Lipoprotein (LDL)-cholesterol and High Density Lipoprotein (HDL)-cholesterol with 95% CI were calculated using linear mixed effects model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Lipid Profile Biomarker Triglycerides Over 12 Weeks</measure>
    <time_frame>Baseline,12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of triglycerides. The mean changes between baseline and 12 weeks in triglycerides with 95% CI were calculated using linear mixed effects model, and the log transformed triglyceride was calculated.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Hemoglobin Over 12 Weeks</measure>
    <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of hemoglobin. The mean changes between baseline, 6 weeks and 12 weeks in hemoglobin with 95% CI were calculated using linear mixed effects model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Plasma Nitrate Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>A blood sample was drawn for each participant to measure the levels of plasma nitrate. The mean changes between baseline, 6 weeks and 12 weeks in plasma nitrate with 95% CI were calculated using linear mixed effects model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Urinary Albumin-to-creatinine Ratios Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>A urine sample was taken for each participant to measure the levels of urinary albumin-to-creatinine ratios. The mean changes between baseline, 6 weeks and 12 weeks in urinary albumin-to-creatinine ratios with 95% CI were calculated using linear mixed effects model, and the log transformed urinary albumin-to-creatinine ratios was calculated.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Blood Pressure Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>Blood pressure was measured using the OMRON HEM-907 XL BP Monitor per standard protocol by trained and certified research staff. The mean changes between baseline, 6 weeks and 12 weeks in blood pressure with 95% CI were calculated using linear mixed effects model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Pulse Over 12 Weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
    <description>Pulse was measured at the brachial artery per standard protocol by trained and certified research staff. The mean changes between baseline, 6 weeks and 12 weeks in pulse with 95% CI were calculated using linear mixed effects model.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>identical placebos.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate release sodium nitrite</intervention_name>
    <description>Immediate release sodium nitrite 40 mg by mouth twice per day</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>TV1001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Isoquercetin</intervention_name>
    <description>Isoquercetin 225 mg by mouth once per day</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>3-O-glucoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebos</intervention_name>
    <description>placebos</description>
    <arm_group_label>Placebos</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 21-74 years old with any race/ethnicity background&#xD;
&#xD;
          -  CKD as defined by an eGFR &lt;60 ml/min/1.73 m2 or urinary albumin to creatinine ratio ≥&#xD;
             30 mg/g or protein to creatinine ratio ≥150 mg/g.&#xD;
&#xD;
          -  Systolic BP≥120 and &lt;180 mmHg and/or diastolic BP≥70 and &lt;110 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic to organic nitrite, isoquercetin, niacin, or vitamin C&#xD;
&#xD;
          -  Institutionalized (e.g., prisoner, nursing home or skilled nursing facility resident)&#xD;
&#xD;
          -  Unable or unwilling to give consent&#xD;
&#xD;
          -  Known HIV infection and/or AIDS&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Currently on dialysis&#xD;
&#xD;
          -  Previous or current organ or bone marrow transplant&#xD;
&#xD;
          -  Receiving immunosuppressive treatment or other immunotherapy&#xD;
&#xD;
          -  Receiving chemotherapy or alkylating agents for systemic cancer&#xD;
&#xD;
          -  Recent acute myocardial infarction, cerebrovascular accidence or transient ischemic&#xD;
             attack, or hospitalization in 3 months&#xD;
&#xD;
          -  Acute kidney injury within the previous 3 months&#xD;
&#xD;
          -  Currently taking a phosphodiesterase-5 enzyme inhibitor, such as Viagra&#xD;
&#xD;
          -  History of chronic headaches&#xD;
&#xD;
          -  Chronically receiving fluoroguinolones, cyclosporin (neural, sandimmune), nitrate&#xD;
             drug, NSAIDS ( except aspirin ≤ 81 mg daily), allopurinol or uloric, meperidine and&#xD;
             related central nervous system (CNS) depressants, oral glucocorticoids, and not&#xD;
             willing or able to stop during study period.&#xD;
&#xD;
          -  Active infection (i.e. systemic or osteomyelitis)&#xD;
&#xD;
          -  Class III or IV heart failure&#xD;
&#xD;
          -  History of hemolytic anemia including sickle cell disease&#xD;
&#xD;
          -  Hemoglobin &lt;10&#xD;
&#xD;
          -  History of chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          -  Have a positive screen for glucose-6-phosphate dehydrogenase (G6PD) deficiency at&#xD;
             screening&#xD;
&#xD;
          -  Involvement in other clinical trials&#xD;
&#xD;
          -  Current alcohol or other substance abuse&#xD;
&#xD;
          -  Current smokers&#xD;
&#xD;
          -  Unwillingness to stop flavonoid supplementation&#xD;
&#xD;
          -  Unwillingness to stop nitrate and/or nitrite supplementation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>participant eligibility is based on self-representation of gender identity.</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tulane School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <results_first_submitted>February 8, 2021</results_first_submitted>
  <results_first_submitted_qc>March 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2021</results_first_posted>
  <disposition_first_submitted>January 11, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>January 11, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 15, 2019</disposition_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endothelial Dysfunction</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>eGFR</keyword>
  <keyword>Urine Albumin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>deidentified data sets may be available to other researchers.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>no end date.</ipd_time_frame>
    <ipd_access_criteria>The de-identified patient level data will be provided directly to the researcher in a secure manner, and the researcher is responsible for protecting the confidentiality and integrity of the data while the research is conducted.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT02552888/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once per day.&#xD;
Immediate release sodium nitrite: Immediate release sodium nitrite 40 mg by mouth twice per day&#xD;
Isoquercetin: Isoquercetin 225 mg by mouth once per day</description>
        </group>
        <group group_id="P2">
          <title>Placebos</title>
          <description>identical placebos.&#xD;
placebos: placebos</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35">35 participants were enrolled.</participants>
                <participants group_id="P2" count="35">35 participants were enrolled.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34">34 participants completed the study.</participants>
                <participants group_id="P2" count="34">34 participants completed the study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once per day.&#xD;
Immediate release sodium nitrite: Immediate release sodium nitrite 40 mg by mouth twice per day&#xD;
Isoquercetin: Isoquercetin 225 mg by mouth once per day</description>
        </group>
        <group group_id="B2">
          <title>Placebos</title>
          <description>identical placebos.&#xD;
placebos: placebos</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="10.4"/>
                    <measurement group_id="B2" value="62.2" spread="10.2"/>
                    <measurement group_id="B3" value="61.8" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Baseline Characteristics of Study Participants by Treatment Allocation</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Metabolic Panel of Study Participants by Treatment Allocation</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Fasting plasma glucose, mean, mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119" spread="44"/>
                    <measurement group_id="B2" value="124" spread="70"/>
                    <measurement group_id="B3" value="121.5" spread="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol, mean, mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178" spread="43"/>
                    <measurement group_id="B2" value="171" spread="50"/>
                    <measurement group_id="B3" value="174.5" spread="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-cholesterol, mean, mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="13"/>
                    <measurement group_id="B2" value="47" spread="14"/>
                    <measurement group_id="B3" value="47.5" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-cholesterol, mean, mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107" spread="34"/>
                    <measurement group_id="B2" value="100" spread="37"/>
                    <measurement group_id="B3" value="103.5" spread="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Blood Pressure of Study Participants by Treatment Allocation</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Systolic blood pressure, mean, mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129" spread="15"/>
                    <measurement group_id="B2" value="129" spread="15"/>
                    <measurement group_id="B3" value="129" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure, mean, mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="7"/>
                    <measurement group_id="B2" value="75" spread="11"/>
                    <measurement group_id="B3" value="74" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Body Mass Index of Study Participants by Treatment Allocation</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" spread="5.6"/>
                    <measurement group_id="B2" value="32.5" spread="5.7"/>
                    <measurement group_id="B3" value="31.7" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Estimated Glomerular Filtration Rate of Study Participants by Treatment Allocation</title>
          <units>ml/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="22"/>
                    <measurement group_id="B2" value="45" spread="16"/>
                    <measurement group_id="B3" value="48" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percentage Change in Endothelium-dependent Flow-mediated Vasodilation (FMD) Over 12 Weeks</title>
        <description>FMD was measured using high resolution ultrasound on the brachial artery. FMD was calculated as the maximal percentage change in vessel size during hyperemia . The mean changes between baseline, 6 weeks and 12 weeks in FMD with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once per day.&#xD;
Immediate release sodium nitrite: Immediate release sodium nitrite 40 mg by mouth twice per day&#xD;
Isoquercetin: Isoquercetin 225 mg by mouth once per day</description>
          </group>
          <group group_id="O2">
            <title>Placebos</title>
            <description>identical placebos.&#xD;
placebos: placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage Change in Endothelium-dependent Flow-mediated Vasodilation (FMD) Over 12 Weeks</title>
          <description>FMD was measured using high resolution ultrasound on the brachial artery. FMD was calculated as the maximal percentage change in vessel size during hyperemia . The mean changes between baseline, 6 weeks and 12 weeks in FMD with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-0.1" upper_limit="2.3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-0.9" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Endothelial Function Biomarkers VCAM-1, ICAM-1, E-selectin and vWF Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of Vascular Adhesion Molecule-1(VCAM-1), Intercellular Adhesion Molecule-1 (ICAM-1), E-selectin, and von Willebrand Factor (vWF). The mean changes between baseline, 6 weeks and 12 weeks in VCAM-1, ICAM-1, E-selectin and vWF with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Endothelial Function Biomarkers VCAM-1, ICAM-1, E-selectin and vWF Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of Vascular Adhesion Molecule-1(VCAM-1), Intercellular Adhesion Molecule-1 (ICAM-1), E-selectin, and von Willebrand Factor (vWF). The mean changes between baseline, 6 weeks and 12 weeks in VCAM-1, ICAM-1, E-selectin and vWF with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ICAM, ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.1" lower_limit="-41.5" upper_limit="9.3"/>
                    <measurement group_id="O2" value="-4.0" lower_limit="-29.0" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VCAM-1, ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.2" lower_limit="-49.3" upper_limit="5.0"/>
                    <measurement group_id="O2" value="-10.8" lower_limit="-37.5" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E-Selecint, ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" lower_limit="-3.14" upper_limit="2.50"/>
                    <measurement group_id="O2" value="1.06" lower_limit="-1.73" upper_limit="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vWF, ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-683" lower_limit="-3784" upper_limit="2419"/>
                    <measurement group_id="O2" value="2744" lower_limit="-328" upper_limit="5815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Endothelial Function Biomarker Asymmetrical DiMethylArginine (ADMA) Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of Asymmetrical DiMethylArginine (ADMA). The mean changes between baseline, 6 weeks and 12 weeks in ADMA with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Endothelial Function Biomarker Asymmetrical DiMethylArginine (ADMA) Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of Asymmetrical DiMethylArginine (ADMA). The mean changes between baseline, 6 weeks and 12 weeks in ADMA with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>umol/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-0.02" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.03" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Endothelial Function Biomarker Endostatin Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of endostatin. The mean changes between baseline, 6 weeks and 12 weeks in endostatin with 95% CI were calculated using linear mixed effects model, and the log transformed endostatin was calculated.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Endothelial Function Biomarker Endostatin Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of endostatin. The mean changes between baseline, 6 weeks and 12 weeks in endostatin with 95% CI were calculated using linear mixed effects model, and the log transformed endostatin was calculated.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>log (ng/mL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.08" upper_limit="0.05"/>
                    <measurement group_id="O2" value="-0.01" lower_limit="-0.08" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Endothelial Function Biomarker Urine Epidermal Growth Factor (UEGF) Over 12 Weeks</title>
        <description>A urine sample was taken for each participant to measure the levels of Urine Epidermal Growth Factor (UEGF). The mean changes between baseline, 6 weeks and 12 weeks in UEGF with 95% CI were calculated using linear mixed effects model, and the log transformed Urine EGF/creatinine ratio was calculated.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Endothelial Function Biomarker Urine Epidermal Growth Factor (UEGF) Over 12 Weeks</title>
          <description>A urine sample was taken for each participant to measure the levels of Urine Epidermal Growth Factor (UEGF). The mean changes between baseline, 6 weeks and 12 weeks in UEGF with 95% CI were calculated using linear mixed effects model, and the log transformed Urine EGF/creatinine ratio was calculated.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>log (pg/g)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" lower_limit="-0.39" upper_limit="0.37"/>
                    <measurement group_id="O2" value="0.23" lower_limit="-0.14" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Inflammatory Biomarker C-Reactive Protein (CRP) Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of C-Reactive Protein (CRP). The mean changes between baseline, 6 weeks and 12 weeks in CRP with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical Placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Inflammatory Biomarker C-Reactive Protein (CRP) Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of C-Reactive Protein (CRP). The mean changes between baseline, 6 weeks and 12 weeks in CRP with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="-0.31" upper_limit="0.42"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-0.38" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Inflammatory Biomarkers Tumor Necrosis Factor-α (TNF-a), Interleukin-17 (IL-17), Interleukin-1β (IL-1beta), and Monocyte Chemoattractant Protein-1 (MCP-1) Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of Tumor Necrosis Factor-α (TNF-a), interleukin-17 (IL-17), interleukin-1β (IL-1beta), and Monocyte Chemoattractant Protein-1 (MCP-1). The mean changes between baseline, 6 weeks and 12 weeks in TNF-a, IL-17, IL-1beta, MCP-1 with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical Placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Inflammatory Biomarkers Tumor Necrosis Factor-α (TNF-a), Interleukin-17 (IL-17), Interleukin-1β (IL-1beta), and Monocyte Chemoattractant Protein-1 (MCP-1) Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of Tumor Necrosis Factor-α (TNF-a), interleukin-17 (IL-17), interleukin-1β (IL-1beta), and Monocyte Chemoattractant Protein-1 (MCP-1). The mean changes between baseline, 6 weeks and 12 weeks in TNF-a, IL-17, IL-1beta, MCP-1 with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TNF-a, pg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-0.20" upper_limit="0.12"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.20" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17, pg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" lower_limit="-1.80" upper_limit="0.36"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-1.05" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1 beta, pg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.1" lower_limit="-77.5" upper_limit="43.4"/>
                    <measurement group_id="O2" value="-30.5" lower_limit="-90.0" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1, pg/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" lower_limit="-25.0" upper_limit="13.0"/>
                    <measurement group_id="O2" value="0.6" lower_limit="-18.0" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Inflammatory Biomarker Interleukin-6 (IL-6) Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of interleukin-6 (IL-6). The mean changes between baseline, 6 weeks and 12 weeks in interleukin-6 (IL-6) with 95% CI were calculated using linear mixed effects model, and the log transformed IL-6 was calculated.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical Placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Inflammatory Biomarker Interleukin-6 (IL-6) Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of interleukin-6 (IL-6). The mean changes between baseline, 6 weeks and 12 weeks in interleukin-6 (IL-6) with 95% CI were calculated using linear mixed effects model, and the log transformed IL-6 was calculated.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>log (pg/mL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="-0.06" upper_limit="0.20"/>
                    <measurement group_id="O2" value="-0.17" lower_limit="-0.30" upper_limit="-0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Oxidative Stress Biomarker Low-density Lipoprotein (LDL) Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of low-density lipoprotein (LDL). The mean changes between baseline, 6 weeks and 12 weeks in LDL with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Oxidative Stress Biomarker Low-density Lipoprotein (LDL) Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of low-density lipoprotein (LDL). The mean changes between baseline, 6 weeks and 12 weeks in LDL with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" lower_limit="-3.9" upper_limit="0.5"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-2.4" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Oxidative Stress Biomarker Nitrotyrosine Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of nitrotyrosine. The mean changes between baseline, 6 weeks and 12 weeks in nitrotyrosine with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Oxidative Stress Biomarker Nitrotyrosine Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of nitrotyrosine. The mean changes between baseline, 6 weeks and 12 weeks in nitrotyrosine with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" lower_limit="-96.9" upper_limit="75.2"/>
                    <measurement group_id="O2" value="62.2" lower_limit="-22.6" upper_limit="147.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Percentage Change in Methemoglobin Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of methemoglobin. The mean percentage change between baseline, 6 weeks and 12 weeks in methemoglobin with 95% CI was calculated using linear mixed effects model.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage Change in Methemoglobin Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of methemoglobin. The mean percentage change between baseline, 6 weeks and 12 weeks in methemoglobin with 95% CI was calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" lower_limit="-0.11" upper_limit="-0.01"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.11" upper_limit="-0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change in Isoquercetin Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of isoquercetin. The mean changes between baseline, 6 weeks and 12 weeks in isoquercetin with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Isoquercetin Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of isoquercetin. The mean changes between baseline, 6 weeks and 12 weeks in isoquercetin with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166" lower_limit="102" upper_limit="230"/>
                    <measurement group_id="O2" value="11.7" lower_limit="-51.1" upper_limit="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change in Plasma Nitrite Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of plasma nitrite. The mean changes between baseline, 6 weeks and 12 weeks in plasma nitrite with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Plasma Nitrite Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of plasma nitrite. The mean changes between baseline, 6 weeks and 12 weeks in plasma nitrite with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>micromol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" lower_limit="-0.20" upper_limit="0.05"/>
                    <measurement group_id="O2" value="-0.11" lower_limit="-0.23" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change in Estimated-Glomerular Filtration Rate (eGFR) Over 12 Weeks</title>
        <description>Estimated-Glomerular Filtration Rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. The equation is GFR = 141 * min(Scr/κ,1)α * max(Scr/κ, 1)-1.209 * 0.993Age * 1.018 [if female] * 1.159 [if black]. Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. The mean changes between baseline, 6 weeks and 12 weeks in eGFR with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Estimated-Glomerular Filtration Rate (eGFR) Over 12 Weeks</title>
          <description>Estimated-Glomerular Filtration Rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. The equation is GFR = 141 * min(Scr/κ,1)α * max(Scr/κ, 1)-1.209 * 0.993Age * 1.018 [if female] * 1.159 [if black]. Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. The mean changes between baseline, 6 weeks and 12 weeks in eGFR with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-2.3" upper_limit="2.5"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-2.2" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change in Lipid Profile Biomarkers Total Cholesterol, Low Density Lipoprotein (LDL)-Cholesterol and High Density Lipoprotein (HDL)-Cholesterol Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of total cholesterol, Low Density Lipoprotein (LDL)-cholesterol and High Density Lipoprotein (HDL)-cholesterol. The mean changes between baseline and 12 weeks in total cholesterol, Low Density Lipoprotein (LDL)-cholesterol and High Density Lipoprotein (HDL)-cholesterol with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>Baseline,12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Lipid Profile Biomarkers Total Cholesterol, Low Density Lipoprotein (LDL)-Cholesterol and High Density Lipoprotein (HDL)-Cholesterol Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of total cholesterol, Low Density Lipoprotein (LDL)-cholesterol and High Density Lipoprotein (HDL)-cholesterol. The mean changes between baseline and 12 weeks in total cholesterol, Low Density Lipoprotein (LDL)-cholesterol and High Density Lipoprotein (HDL)-cholesterol with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol, mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" lower_limit="-10.5" upper_limit="7.2"/>
                    <measurement group_id="O2" value="3.9" lower_limit="-4.9" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-cholesterol, mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" lower_limit="-7.4" upper_limit="3.7"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-7.4" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-cholesterol, mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="-1.7" upper_limit="3.4"/>
                    <measurement group_id="O2" value="2.2" lower_limit="-0.4" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change in Lipid Profile Biomarker Triglycerides Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of triglycerides. The mean changes between baseline and 12 weeks in triglycerides with 95% CI were calculated using linear mixed effects model, and the log transformed triglyceride was calculated.</description>
        <time_frame>Baseline,12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Lipid Profile Biomarker Triglycerides Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of triglycerides. The mean changes between baseline and 12 weeks in triglycerides with 95% CI were calculated using linear mixed effects model, and the log transformed triglyceride was calculated.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>log (mg/dL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" lower_limit="-0.4" upper_limit="4.7"/>
                    <measurement group_id="O2" value="-0.01" lower_limit="-0.14" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change in Hemoglobin Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of hemoglobin. The mean changes between baseline, 6 weeks and 12 weeks in hemoglobin with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Hemoglobin Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of hemoglobin. The mean changes between baseline, 6 weeks and 12 weeks in hemoglobin with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" lower_limit="-0.46" upper_limit="-0.04"/>
                    <measurement group_id="O2" value="-0.13" lower_limit="-0.34" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change in Plasma Nitrate Over 12 Weeks</title>
        <description>A blood sample was drawn for each participant to measure the levels of plasma nitrate. The mean changes between baseline, 6 weeks and 12 weeks in plasma nitrate with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Plasma Nitrate Over 12 Weeks</title>
          <description>A blood sample was drawn for each participant to measure the levels of plasma nitrate. The mean changes between baseline, 6 weeks and 12 weeks in plasma nitrate with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="5.9" upper_limit="25.0"/>
                    <measurement group_id="O2" value="-6.3" lower_limit="-15.7" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change in Urinary Albumin-to-creatinine Ratios Over 12 Weeks</title>
        <description>A urine sample was taken for each participant to measure the levels of urinary albumin-to-creatinine ratios. The mean changes between baseline, 6 weeks and 12 weeks in urinary albumin-to-creatinine ratios with 95% CI were calculated using linear mixed effects model, and the log transformed urinary albumin-to-creatinine ratios was calculated.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Urinary Albumin-to-creatinine Ratios Over 12 Weeks</title>
          <description>A urine sample was taken for each participant to measure the levels of urinary albumin-to-creatinine ratios. The mean changes between baseline, 6 weeks and 12 weeks in urinary albumin-to-creatinine ratios with 95% CI were calculated using linear mixed effects model, and the log transformed urinary albumin-to-creatinine ratios was calculated.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>log (mg/g)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-0.27" upper_limit="0.36"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.29" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change in Blood Pressure Over 12 Weeks</title>
        <description>Blood pressure was measured using the OMRON HEM-907 XL BP Monitor per standard protocol by trained and certified research staff. The mean changes between baseline, 6 weeks and 12 weeks in blood pressure with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Blood Pressure Over 12 Weeks</title>
          <description>Blood pressure was measured using the OMRON HEM-907 XL BP Monitor per standard protocol by trained and certified research staff. The mean changes between baseline, 6 weeks and 12 weeks in blood pressure with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure, mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" lower_limit="-6.8" upper_limit="2.4"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-5.3" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure, mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-5.0" upper_limit="-0.1"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-2.3" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change in Pulse Over 12 Weeks</title>
        <description>Pulse was measured at the brachial artery per standard protocol by trained and certified research staff. The mean changes between baseline, 6 weeks and 12 weeks in pulse with 95% CI were calculated using linear mixed effects model.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
        <population>Mean Changes Over 12 Weeks (95% CI)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>identical placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Pulse Over 12 Weeks</title>
          <description>Pulse was measured at the brachial artery per standard protocol by trained and certified research staff. The mean changes between baseline, 6 weeks and 12 weeks in pulse with 95% CI were calculated using linear mixed effects model.</description>
          <population>Mean Changes Over 12 Weeks (95% CI)</population>
          <units>beat/minute</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="-1.7" upper_limit="2.3"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-2.8" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each participant was assessed for adverse events in the duration of 3 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once per day.&#xD;
Immediate release sodium nitrite: Immediate release sodium nitrite 40 mg by mouth twice per day&#xD;
Isoquercetin: Isoquercetin 225 mg by mouth once per day</description>
        </group>
        <group group_id="E2">
          <title>Placebos</title>
          <description>identical placebos.&#xD;
placebos: placebos</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Serious Adverse Event - Inpatient hospitalization</sub_title>
                <description>One SAE in the treatment group included a hospitalization for new onset atrial fibrillation due to a massively dilated left atrium.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.75</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Events</sub_title>
                <counts group_id="E1" events="55" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E2" events="63" subjects_affected="14" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jing Chen</name_or_title>
      <organization>Tulane School of Medicine</organization>
      <phone>5049886110</phone>
      <email>jchen@tulane.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

